oral genome We are pleased to announce the appointment of Michael Schumann as Chief Revenue Officer. Shuman brings extensive experience leading high-growth organizations in the dental industry, most recently as CEO of Membersy, where he helped build a national footprint and drive commercial results.
In his new role, Schumann will oversee commercial strategy, corporate development and dental partnership expansion to accelerate the nationwide adoption of Oral Genomics' rapid saliva-based testing.
“We are pleased to welcome Michael to Oral Genome,” said Dr. Tina Saw, founder and CEO. “His record of leading transformative growth aligns perfectly with our mission to bring preventive testing to every dental practice.”
“What attracted me to Oral Genome is our mission to empower service providers to detect preventable problems before they occur,” said Michael Human, chief risk officer. “I have spent my career helping dental organizations modernize the way they deliver value to patients, and Oral Genome represents the next step in that journey. By combining clinical insights with scalable technology, we are creating a pathway for every practice to take an active role in early detection and systemic health. I'm excited to help expand access and adoption among healthcare organizations across the country.”
About the oral genome
Oral Genome is a health technology company developing saliva-based oral and systemic health testing. Its mission is to advance preventive care by making fast, convenient, and impactful testing available to all.
sevenThe biotech startup, which uses transformer-based artificial intelligence to detect organ-specific signals of chronic diseases, has secured $6.7 million in seed funding, according to a press release. Felicis Ventures and Illumina Ventures led the round. SeaX Ventures, Alumni Ventures and AME Cloud Ventures also participated. The company was founded by former leaders from Illumina, Grail and Google, who are applying technical, genomic and commercialization expertise from their liquid biopsy work to chronic diseases.
Hamed Amini, co-founder and CEO of Hepta, explains its approach to treating metabolic dysfunction-associated steatohepatitis (MASH).
“Our team develops next-generation sequencing technology at Illumina and at Grail Building and scaling a first-generation liquid biopsy platform, it has now been demonstrated that a simple blood draw can replicate tissue-level biology. This provides the foundation for non-invasive diagnostics to guide precision treatment of chronic diseases, starting with MASH, a systemic metabolic disease that affects tens of millions of people in the United States alone, where access to care is unfortunately limited by invasive, outdated or highly specialized tools. In addition to testing, our platform has the potential to serve as a single source of guidance for treatment and monitoring of response.”
To learn more, click here.
Aramco HealthA public benefit company focused on serious mental illness has raised $25 million in pre-emptive Series B funding to transform the way serious mental illness is understood, treated and cured, according to a press release. Altos Ventures led the round, with participation from all existing investors, including Quiet Capital, Bling Capital, Cedars-Sinai Ventures, Healthier Capital and 8VC.
The new funding will be used to support the opening of Amae clinics across the country, advance its proprietary AI-driven care platform, and support research into schizophrenia, bipolar disorder, and treatment-resistant depression. It will also strengthen partnerships with academic medical centers to expand access to Amae's comprehensive care model.
“Serious mental illness takes a devastating toll on families and communities, but traditional treatment models are not working,” said Stas Sokolin, co-founder and CEO of Amae Health. “We are taking a different path; combining compassionate, face-to-face care with responsible deployment of artificial intelligence to help clinicians determine the best options for each individual.”
To learn more, click here.
HiluxThe company, a therapeutic company developing novel targeted drugs for inherited kidney diseases, raised an oversubscribed $3.5 million in seed funding, according to a press release. investor pi The round was led by Ventures, with participation from Bluehill Capital, SOSV and a global investor consortium. Helex has raised over $6 million in funding to date.
Helex hopes to transform the treatment of chronic and rare kidney diseases by developing programmable, non-viral lipid nanoparticle therapeutics that deliver therapeutics directly to kidney cells. This approach opens the door to a new class of targeted disease-modifying drugs for millions of patients who currently have no effective treatment options.
Its leading project targets autosomal dominant polycystic kidney disease, a genetic disease caused by mutations in the PKD1 or PKD2 genes. The disease affects more than 12 million people worldwide, causing the progressive formation of kidney cysts and decreased kidney function. ADPKD patients eventually face dialysis or kidney transplantation. Helex aims to change that with a single-dose, non-viral gene-editing therapy that can halt or significantly slow disease progression.
To learn more, click here.
image: Studio J, Getty Images
This is a paid membership feature medical citizenship. Submit here and join!
